Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Topics to Be Discussed

• Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)
• Ocular Toxicities and Other Tolerability Considerations with ADCs for MM
• Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for MM to facilitate their integration into management algorithms.
• Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
• Implement a plan of care to recognize and manage the toxicities associated with bispecific antibodies and ADCs commonly used for MM in order to maintain patient quality of life and time on treatment.
• Assess available research data with BCMA-directed bispecific antibodies for patients with relapsed/refractory (R/R) MM, and appreciate the clinical role of these agents.
• Recall recently presented clinical trial results establishing the definitive efficacy of BCMA-directed bispecific antibody therapy in combination with anti-CD38 monoclonal antibody therapy for patients with R/R MM, and integrate this novel therapeutic strategy into management algorithms.
• Recall available data with novel bispecific antibody- and ADC-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Cohen — Advisory Committees: Genentech, a member of the Roche Group, GSK, Ichnos Glenmark Innovation Inc, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Novartis; Consulting Agreements: AbbVie Inc, Arcellx, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Genentech, a member of the Roche Group, GSK, Ichnos Glenmark Innovation Inc, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Moderna, Pfizer Inc, Prothena, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc; Data and Safety Monitoring Boards/Committees: GSK, Janssen Biotech Inc, Kite, A Gilead Company. Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma, Takeda Pharmaceutical Company Limited. Dr Trudel — Advisory Committees: AstraZeneca Pharmaceuticals LP, GSK, Janssen Biotech Inc, Kite, A Gilead Company, Opna Bio, Pfizer Inc, Sanofi; Consulting Agreements: GSK; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Pfizer Inc, Roche Laboratories Inc.

MODERATOR
Dr Callander has no relevant financial relationships to disclose. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 3:15 PM to 5:15 PM central time (4:15 PM to 6:15 PM eastern time).

Topics to Be Discussed

• Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias
• Managing MF in Patients with Anemia
• Managing MF in Patients with Thrombocytopenia
• Novel Approaches for MF Potentially Nearing the Clinic
• Other Promising Novel Agents Under Investigation for MF

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis (MF).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with MF regarding their long-term prognosis.
• Analyze how age, performance status and other biological and disease-related factors affect the decision to initiate therapy and the subsequent selection of treatment for patients with primary and secondary MF.
• Appraise available research informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with anemia, thrombocytopenia or compromised renal function, and personalize treatment recommendations based on this information.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
• Review available research data with and the current clinical role of novel JAK inhibitors for patients with MF and severe thrombocytopenia.
• Understand the biological rationale for the inhibition of exportin 1 (XPO1) in patients with MF, and reflect on available research findings with XPO1 inhibitors in combination with JAK inhibition as front-line treatment.
• Recall available research findings with combination regimens incorporating JAK inhibitors and other novel investigational agents, such as BET inhibitors and MDM2 inhibitors, and consider the potential role of these emerging approaches.
• Recognize the spectrum, frequency and severity of side effects associated with JAK inhibitors and other therapies employed in the treatment of MF, and implement a plan of care to recognize, prevent and manage resultant toxicities.
• Assess the mechanism of action of, available research findings with and ongoing investigation of other novel agents for MF, and consider the potential clinical application of these approaches.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Masarova — Advisory Committees: Cogent Biosciences, Karyopharm Therapeutics, PharmaEssentia. Dr Mesa — Consulting Agreements: Bristol Myers Squibb, Genentech, a member of the Roche Group, Geron Corporation, GSK, Incyte Corporation, Lilly, PharmaEssentia, Sobi, Takeda Pharmaceuticals USA Inc, Telios Pharma Inc; Contracted Research: Incyte Corporation, PharmaEssentia; Data and Safety Monitoring Boards/Committees: Geron Corporation, Kartos Therapeutics, Telios Pharma Inc. Dr Passamonti — Advisory Committees: AbbVie Inc, Bristol Myers Squibb, GSK, Kartos Therapeutics, Karyopharm Therapeutics, Menarini Group, Novartis, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma, Takeda Pharmaceutical Company Limited; Data and Safety Monitoring Boards/Committees: Menarini Group (myeloma study); Speakers Bureaus: AOP Orphan Pharmaceuticals GmbH, Bristol Myers Squibb, GSK, Incyte Corporation, Menarini Group, Novartis, Stemline Therapeutics Inc. Dr Rampal — Consulting Agreements: AbbVie Inc, Blueprint Medicines, Bristol Myers Squibb, Cogent Biosciences, CTI BioPharma, a Sobi Company, Disc Medicine, Galecto Inc, GSK, Incyte Corporation, Jazz Pharmaceuticals Inc, Kartos Therapeutics, Karyopharm Therapeutics, MorphoSys, Novartis, Opna Bio, PharmaEssentia, Roche Laboratories Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Zentalis Pharmaceuticals; Contracted Research: BioMed Valley Discoveries, Incyte Corporation, MorphoSys, Ryvu Therapeutics, Stemline Therapeutics Inc, Zentalis Pharmaceuticals; Data and Safety Monitoring Boards/Committees: Merck.

MODERATOR
Dr Kuykendall — Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Cogent Biosciences, CTI BioPharma, a Sobi Company, Deciphera Pharmaceuticals Inc, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Merck, Novartis, Ono Pharmaceutical Co Ltd, Opna Bio, PharmaEssentia, Protagonist Therapeutics Inc, Silence Therapeutics, Takeda Pharmaceuticals USA Inc; Contracted Research: Ajax Therapeutics, Blueprint Medicines, Bristol Myers Squibb, Geron Corporation, GSK, Janssen Biotech Inc, Kartos Therapeutics, Novartis, Protagonist Therapeutics Inc. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, and Novartis.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Faculty

Toby A Eyre

MBChB, DipMedEd, MRCP, MD

Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Headington, Oxford, United Kingdom

Haematology Consultant, Honorary Senior Clinical Lecturer in Haematology

Faculty

Talha Munir

MBBS, MRCP, PhD

St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Consultant Hematologist

Faculty

Mazyar Shadman

MD, MPH

Fred Hutchinson Cancer Center and University of Washington, Seattle, Washington

Harr Family Endowed Chair in Immunotherapy, Deputy Chief Medical Officer, Medical Director, Cellular Immunotherapy, Professor, Clinical Research Division

Moderator

Shazia Nakhoda

MD

Fox Chase Cancer Center, Philadelphia, Pennsylvania

Assistant Professor in the Department of Hematology/Oncology

Faculty

William G Wierda

MD, PhD

The University of Texas MD Anderson Cancer Center, Houston, Texas

Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr Elihu Estey, Section Chief, Chronic Lymphocytic Leukemia, Center Medical Director, Department of Leukemia, Division of Cancer Medicine, Deputy Division Head for Clinical and Educational Affairs

Additional faculty to be announced.

Join us on Friday, December 11^th from 7:30 AM to 9:30 AM central time (8:30 AM to 10:30 AM eastern time).

Topics to Be Discussed

• Front-Line Therapy for Patients with Chronic Lymphocytic Leukemia (CLL) without High-Risk Features 
• Initial Treatment for High-Risk CLL 
• Available Data with and Role of Noncovalent Bruton Tyrosine Kinase Inhibitor Therapy for Newly Diagnosed CLL 
• Selection and Sequencing of Therapy for Relapsed/Refractory CLL 
• Novel Agents in Clinical Development for CLL 

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients with newly diagnosed disease. 
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences. 
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents. 
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options. 
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL to effectively inform patients about the risks and benefits of this novel treatment strategy. 
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review available data with this strategy in patients with newly diagnosed and relapsed/refractory (R/R) CLL. 
• Appraise clinical investigator best practices for various R/R CLL management situations, and use this information to facilitate improved clinical decision-making. 
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL and, where applicable, discuss clinical trial participation with eligible patients. 

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — Dr Munir has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Eyre — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Autolus, BeOne, Bristol Myers Squibb, Galapagos NV, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Kite, A Gilead Company, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Roche Laboratories Inc. Dr Shadman — Advisory Committees and Consulting Agreements: AbbVie Inc, ADC Therapeutics, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Fate Therapeutics, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Kite, A Gilead Company, Lilly, Merck, MorphoSys, Nurix Therapeutics Inc, Pfizer Inc, Pierre Fabre; Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Janssen Biotech Inc, Merck, MorphoSys, Nurix Therapeutics Inc, Sana Biotechnology; Stock OPTIONS — Private Companies: Koi Biotherapeutics Inc; Nonrelevant Financial Relationships: Bristol Myers Squibb (spouse employment). Dr Wierda — Consulting/Advisory Boards, No Compensation: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Intellisphere, Johnson & Johnson, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Bristol Myers Squibb Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Nurix Therapeutics Inc, Pharmacyclics LLC, an AbbVie Company; Nonrelevant Financial and Nonfinancial Relationships: National Comprehensive Cancer Network (Chair, CLL), Supported by the NIH/NCI under award number P30 CA016672 and used MD Anderson Cancer Center Support Grant (CCSG) shared resources, Wiley China (consulting/advisory board, no compensation). Additional faculty to be announced.

MODERATOR
Dr Nakhoda — Contracted Research: AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, BeOne, and Lilly.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

Topics to Be Discussed

• Current Use of BCMA-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Multiple Myeloma
• Tolerability Considerations with BCMA-Targeted CAR T-Cell Therapy

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Understand the mechanism of action of BCMA-directed chimeric antigen receptor (CAR) T-cell therapy for patients with MM, and appreciate the similarities and differences among currently available and investigational agents in this class.
• Develop an understanding of the current clinical research database with FDA-approved BCMA-directed CAR T-cell therapy platforms in the management of relapsed/refractory MM in order to optimally integrate this novel therapeutic strategy into treatment algorithms.
• Appreciate the scientific justification for the development of next-generation BCMA-directed CAR T-cell approaches, and appraise available research findings with and ongoing efforts attempting to definitively establish the efficacy and safety of these agents.
• Review the biological rationale for and published research findings with CAR T-cell therapy targeting GPRC5D (G protein-coupled receptor class C group 5 member D) for MM, and evaluate the potential role of this therapeutic strategy.
• Understand the pathophysiology of cytokine release syndrome and neurologic toxicity associated with CAR T-cell therapy for MM, and develop strategies to optimally identify and manage these side effects.
• Recognize the spectrum, frequency and severity of other adverse events, such as secondary hematologic cancer, infections and cytopenias, associated with CAR T-cell therapy used in the care of patients with MM, and consider recommended approaches to prevent, ameliorate and manage these toxicities.
• Recall available data with novel CAR T-cell therapy-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Larson — Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc; Contracted Research: Bristol Myers Squibb, Janssen Biotech Inc, Kite, A Gilead Company, Pfizer Inc, Regeneron Pharmaceuticals Inc; Speakers Bureaus: Regeneron Pharmaceuticals Inc; Stock OPTIONS — Private Companies: TORL BioTherapeutics (founders’ shares). Dr Richard — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Legend Biotech; Consulting Agreements: Bristol Myers Squibb, Karyopharm Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, C4 Therapeutics, Heidelberg Pharma AG, Johnson & Johnson. Additional faculty to be announced.

MODERATOR
Dr Voorhees — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CellCentric, GSK, Johnson & Johnson, Kite, A Gilead Company, Legend Biotech, Predicta Biosciences, Regeneron Pharmaceuticals Inc; Consulting Agreements: Karyopharm Therapeutics; Contracted Research: AbbVie Inc, GSK, Johnson & Johnson, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationships: Multiple Myeloma Research Consortium. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP and Bristol Myers Squibb.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 11:30 AM to 1:30 PM central time (12:30 PM to 2:30 PM eastern time).

Topics to Be Discussed

• Bispecific Antibody Therapy for Diffuse Large B-Cell Lymphoma
• Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes
• Novel Bispecific Antibodies Undergoing Evaluation for Non-Hodgkin Lymphoma
• Tolerability Considerations with CD20 x CD3 Bispecific Antibodies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma (NHL).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Appraise the scientific justification for the evaluation of CD20 x CD3 bispecific antibodies for patients with various forms of NHL, and assess the similarities and differences among available agents in this class.
• Evaluate the available clinical research database with CD20 x CD3 bispecific antibodies in the management of diffuse large B-cell lymphoma (DLBCL), and optimally incorporate this approach into current treatment algorithms.
• Assess available research findings with CD20 x CD3 bispecific antibodies for follicular lymphoma (FL), and identify patients for whom this therapeutic modality should be considered and/or recommended.
• Evaluate published clinical research data with CD20 x CD3 bispecific antibodies in combination with other systemic therapies, and consider the current implications of these findings for DLBCL and FL management.
• Develop an understanding of the biological rationale for and current clinical research database with investigational CD19 x CD3 bispecific antibodies in the management of NHL, and reflect on the ongoing evaluation and potential role of these agents.
• Recognize adverse events associated with available and investigational bispecific antibodies, and implement strategies to educate patients and manage complications.
• Recall ongoing studies attempting to further define the optimal role of bispecific antibody-based strategies in therapy for NHL, and appropriately counsel patients regarding clinical trial participation.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Bartlett — Advisory Committees: ADC Therapeutics; Contracted Research: AbbVie Inc, Allogene Therapeutics, Autolus, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Celgene Corporation, Genentech, a member of the Roche Group, Genmab US Inc, Kite, A Gilead Company, Lilly, Seagen Inc, Takeda Pharmaceuticals USA Inc, Treeline Biosciences. Prof Cheah — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP, Regeneron Pharmaceuticals Inc. Dr Falchi — Advisory Committees: AbbVie Inc, ADC Therapeutics, Bristol Myers Squibb, Chugai Pharmaceutical Co Ltd, Genentech, a member of the Roche Group, Genmab US Inc, Ipsen Biopharmaceuticals Inc, Johnson & Johnson, Regeneron Pharmaceuticals Inc, Seagen Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Genmab US Inc, Merck, NOBO Medicine, Roche Laboratories Inc, Sanofi; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Innate Pharma, Roche Laboratories Inc; Honoraria: AbbVie Inc, Chugai Pharmaceutical Co Ltd, Genmab US Inc, Kite, A Gilead Company, Roche Laboratories Inc; Travel Support: AbbVie Inc, Chugai Pharmaceutical Co Ltd, Genmab US Inc, Kite, A Gilead Company, Roche Laboratories Inc. 

MODERATOR
Dr Patel — Advisory Committees (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck; Consulting Agreements (All Paid to Institution): AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck, Pfizer Inc, Sanofi; Contracted Research (All Paid to Institution): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Immunome, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell, Merck.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Genmab US Inc.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Join us on Friday, December 11^th from 7:30 AM to 9:30 AM central time (8:30 AM to 10:30 AM eastern time).

Topics to Be Discussed

• Nontargeted Treatment for Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (AML) 
• Role of FLT3 Inhibition in AML Management 
• IDH1/2-Targeted Therapy for AML 
• Current and Future Use of Menin Inhibitors for AML 
• Other Novel Agents and Strategies Under Investigation for AML  

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for individuals with primary and secondary AML to optimize clinical and quality of life outcomes. 
• Evaluate the biological rationale for and available research findings with Bcl-2-targeted therapy for patients with AML, and appraise the current role of this strategy. 
• Assess the scientific justification for and published research findings with oral hypomethylating agent therapy for AML to determine the current and appropriate clinical application of this therapeutic approach. 
• Reflect on available research evidence with approved FLT3 inhibitors, and use this information to guide the clinical management of newly diagnosed or progressive AML harboring a FLT3 mutation. 
• Understand available efficacy and safety data with IDH1 inhibitors for patients with IDH1 mutation-positive AML, and integrate this novel approach into current treatment algorithms. 
• Recognize the scientific justification for the development of menin inhibitors for the treatment of certain genetically defined subsets of AML, and consider available research findings with and the current and potential role of these novel agents. 
• Review the biological rationale for, published efficacy and safety data with and ongoing evaluation of CD123-targeted therapy for patients with AML, and consider the future role of these agents. 
• Understand the spectrum, incidence and severity of side effects associated with targeted therapies employed in AML management, and develop appropriate monitoring and management protocols. 
• Recall new data with novel agents and strategies currently under investigation for AML, and discuss ongoing trial opportunities with eligible patients. 

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY — Prof de Botton has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr DiNardo — Advisory Committees: Astellas, Daiichi Sankyo Inc, Kura Oncology, Pfizer Inc, Syndax Pharmaceuticals, SystImmune Inc; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Rigel Pharmaceuticals Inc, Ryvu Therapeutics, Servier Pharmaceuticals LLC, Solu Therapeutics; Contracted Research: AbbVie Inc, Auron Therapeutics, Bristol Myers Squibb, PMV Pharmaceuticals, Remix Therapeutics, Rigel Pharmaceuticals Inc, Servier Pharmaceuticals LLC, SystImmune Inc; Data and Safety Monitoring Boards/Committees: Genmab US Inc. Dr Erba — Advisory Committees: Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Sumitomo Pharma America; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, GlycoMimetics Inc, Kura Oncology, Schrödinger, Servier Pharmaceuticals LLC, Stemline Therapeutics Inc, Sumitomo Pharma America, Taiho Oncology Inc; Contracted Research: Agios Pharmaceuticals Inc, ALX Oncology, Aptose Biosciences Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc, ImmunoGen Inc, Kura Oncology, MacroGenics Inc, Novartis, Oryzon, Rigel Pharmaceuticals Inc, Sumitomo Pharma America, Taiho Oncology Inc; Speakers Bureaus: AbbVie Inc, Incyte Corporation, Jazz Pharmaceuticals Inc, Kura Oncology, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals. Prof Wei — Advisory Committees: AbbVie Inc, Aculeus Therapeutics, Astellas, BeOne, Bristol Myers Squibb, Geron Corporation, Johnson & Johnson, Molecular Partners, Pfizer Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Consulting Agreements: Cycuria Therapeutics, Johnson & Johnson, Servier Pharmaceuticals LLC; Contracted Research: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Dimericon Therapeutics, Johnson & Johnson, Mendus, PharmaEngine Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals; Financial Benefits via Institution: The Walter and Eliza Hall Institute (WEHI) receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof Wei is an employee of WEHI and receives such a financial benefit; Speakers Bureaus: AbbVie Inc, Astellas.

MODERATOR
Dr Fathi — Consulting Agreements: AbbVie Inc, Astellas, AstraZeneca Pharmaceuticals LP, Autolus, Azurity Pharmaceuticals, BeOne, Bristol Myers Squibb, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Genmab US Inc, Johnson & Johnson, Kura Oncology, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, Thermo Fisher Scientific; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Genentech, a member of the Roche Group, Kura Oncology, Servier Pharmaceuticals LLC.

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, Astellas, Daiichi Sankyo Inc, Kura Oncology, Rigel Pharmaceuticals Inc, Sumitomo Pharma America, and Taiho Oncology Inc.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom A/B — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Wednesday, September 2, 2026
5:00 PM – 6:30 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Diffuse Large B-Cell Lymphoma 
• Follicular Lymphoma and Mantle Cell Lymphoma  
• Chronic Lymphocytic Leukemia 

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Develop an understanding of published clinical research findings with CD19-targeted monoclonal antibodies for newly diagnosed and relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).  
• Appraise the biological rationale for, available research findings with and current clinical role of antibody-drug conjugates for R/R DLBCL.  
• Evaluate the mechanism of action of and available clinical trial findings with bispecific T-cell engaging antibodies alone and in combination with other agents for FL, DLBCL and other forms of lymphoma.  
• Appreciate the biological rationale for, available data with and current clinical role of covalent and noncovalent Bruton tyrosine kinase (BTK) and Bcl-2 inhibitors for mantle cell lymphoma.  
• Recognize the prognostic and clinical significance of various biomarkers in chronic lymphocytic leukemia (CLL), such as del(17p), TP53 mutations and IGHV gene rearrangements, and use this information to individualize the selection of systemic therapy for patients with newly diagnosed disease. 
• Review the similarities and differences between covalent and noncovalent BTK inhibitors, and assess the implications for the efficacy and tolerability of these agents.  
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL.  
• Appreciate the scientific rationale for the investigation of covalent and noncovalent BTK inhibitors in combination with Bcl-2 inhibition, and review recently presented data with this strategy for newly diagnosed and R/R CLL.  
• Recall new data with agents and strategies currently under investigation for CLL and various non-Hodgkin lymphoma subtypes, and discuss ongoing trial opportunities with eligible patients. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Kahl — Consulting Agreements: AbbVie Inc, ADC Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Genmab US Inc, Incyte Corporation, Lilly, Octapharma, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: Acrotech Biopharma, Bristol Myers Squibb, Foresight Diagnostics, a wholly-owned subsidiary of Natera Inc, Nurix Therapeutics Inc, PeproMene Bio Inc. Dr Sharman — Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Lilly, Merck, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne. Dr Siddiqi —  Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, Merck, Pfizer Inc; Contracted Research: Bristol Myers Squibb.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genmab US Inc and Lilly.

This event has passed.

Thursday, September 17, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• New Developments in the Management of Previously Untreated Chronic Lymphocytic Leukemia (CLL)
• Selection and Sequencing of Therapies for Relapsed/Refractory CLL

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to

• Recognize the prognostic and clinical significance of various biomarkers (eg, del[17p], TP53 mutations, IGHV gene rearrangements) in chronic lymphocytic leukemia (CLL), and refine molecular testing algorithms for patients newly diagnosed with this disease.
• Individualize the selection of systemic therapy for newly diagnosed CLL, considering risk profile, clinical presentation, coexisting medical conditions and patient preferences.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available clinical research demonstrating the efficacy and safety of covalent and noncovalent BTK inhibitors for newly diagnosed and relapsed/refractory (R/R) CLL, and identify patients for whom treatment with these agents would be appropriate.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data with this strategy for patients with newly diagnosed and R/R CLL.
• Appraise clinical investigator best practices for various CLL management situations, and leverage this information to facilitate improved clinical decision-making.
• Recall available and emerging data with novel agents and combination strategies currently under investigation for CLL, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be announced.

FACULTY
Dr Coombs — Advisory Committees: AbbVie Inc, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, Invivyd, Janssen Biotech Inc, Johnson & Johnson, Lilly, Octapharma, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Carna Biosciences, Lilly; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, BeOne, Lilly; Stock Options/Stock — Public Companies: Geron Corporation. Dr Davids — Consulting Agreements: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Galapagos NV, Genentech, a member of the Roche Group, Genmab US Inc, Janssen Scientific Affairs LLC, Lilly, MEI Pharma Inc, Merck, Nuvalent, Schrödinger; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Flindr Therapeutics, MEI Pharma Inc; Nonrelevant Financial Relationships: UpToDate.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Lilly.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

Wednesday, August 26, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Ovarian Cancer
• Endometrial Cancer
• Cervical Cancer

Target Audience
This activity is intended for gynecologic oncologists, medical oncologists, gynecologists and other healthcare providers involved in the diagnosis and treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced ovarian cancer (OC), and as appropriate, provide counsel regarding personalized treatment recommendations.
• Recognize the rationale for targeting folate receptor alpha (FRα) in OC, and understand the mechanism of action of and available research findings with FRα-directed antibody-drug conjugates (ADCs). 
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and integrate this novel approach into current management algorithms. 
• Appreciate available research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the role of this novel therapeutic strategy in clinical practice.
• Appreciate available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy and as monotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and optimally incorporate these agents into the care of patients with microsatellite instability-high/mismatch repair-deficient and microsatellite-stable/mismatch repair-proficient disease. 
• Recognize the biological rationale for the evaluation of novel ADCs with various targets (eg, TROP2, CDH6, B7-H4) for patients with OC, EC and cervical cancer (CC), and consider available and emerging research findings with and the potential role of these agents. 
• Describe the scientific justification for, published data with and current research studies of other novel agents and strategies for OC, EC and CC, and effectively prioritize clinical trial opportunities for eligible patients.  

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Konecny has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships:

Dr Slomovitz — Consulting Agreements: Aadi Bioscience, AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, BioNTech SE, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Eisai Inc, Genmab US Inc, GSK, Incyte Corporation, Karyopharm Therapeutics, Merck; Data and Safety Monitoring Boards/Committees: Genelux Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Corcept Therapeutics Inc and GSK.

This event has passed.

Tuesday, August 25, 2026
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Where We Are: Biology of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) and Current Treatment Landscape 
• Where We’re Going: Future Directions in the Management of KRAS G12C-Mutant NSCLC 

Target Audience
This activity is intended for medical oncologists, radiation oncologists, surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Recognize the molecular heterogeneity of non-small cell lung cancer (NSCLC), and appreciate the biological rationale for efforts to exploit documented abnormalities in the KRAS pathway.  
• Assess published clinical trial data informing the use of FDA-approved KRAS G12C inhibitors for patients with previously treated metastatic NSCLC harboring a KRAS G12C mutation, and optimally incorporate these agents into current management algorithms.  
• Develop an understanding of the rationale for, unique characteristics of and available and emerging data with novel small-molecule inhibitors of KRAS G12C in order to determine the potential applicability of these agents.  
• Appreciate the side effects and toxicities associated with approved and investigational KRAS G12C inhibitors, and enact support measures to maintain quality of life and continuation of treatment.  
• Recollect the designs of ongoing clinical trials attempting to further define the optimal use of KRAS G12C inhibitors for lung cancer in order to counsel patients regarding study participation. 

CE Credit
CME and ABIM MOC credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) 
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Prof Peters — Advisory Committees and Consulting Agreements (All Fees to Institution): AbbVie Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeOne, BerGenBio ASA, Bicycle Therapeutics, Biocartis, BioInvent, BioNTech SE, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Debiopharm, F-star Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, GSK, HUTCHMED, Illumina, Incyte Corporation, Ipsen Biopharmaceuticals Inc, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck Serono, MSD, Novartis, Novocure Inc, Nuvalent, Nuvation Bio Inc, Nykode Therapeutics, Pfizer Inc, PharmaMar, Promontory Therapeutics Inc, Qlucore AB, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc, Transgene, Zymeworks Inc; Speakers Bureaus (All Fees to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Foundation Medicine, Genentech, a member of the Roche Group, GSK, Illumina, Ipsen Biopharmaceuticals Inc, Lilly, MSD, Novartis, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc. Dr Sabari — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Janssen Biotech Inc, Johnson & Johnson, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc. 

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from Lilly.

This event has passed.